NASDAQ:AMRSAmyris Stock Price, Forecast & News

Amyris' stock was trading at $2.96 on March 11th, 2020 when COVID-19 (Coronavirus) reached pandemic status according to the World Health Organization. Since then, AMRS stock has increased by 61.5% and is now trading at $4.78. View which stocks have been most impacted by Coronavirus.

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Amyris in the last year. There are currently 2 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Amyris.

Amyris is scheduled to release its next quarterly earnings announcement on Monday, October 5th 2020. View our earnings forecast for Amyris.

Amyris Inc (NASDAQ:AMRS) issued its quarterly earnings data on Friday, May, 8th. The biotechnology company reported ($0.56) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.19) by $0.37. The biotechnology company had revenue of $29.13 million for the quarter, compared to the consensus estimate of $34.51 million. View Amyris' earnings history.

Amyris's stock reverse split before market open on Tuesday, June 6th 2017. The 1-15 reverse split was announced on Tuesday, June 6th 2017. The number of shares owned by shareholders was adjusted after the market closes on Monday, June 5th 2017. An investor that had 100 shares of Amyris stock prior to the reverse split would have 7 shares after the split.

Amyris updated its FY 2020 Pre-Market earnings guidance on Friday, May, 8th. The company provided EPS guidance of for the period. The company issued revenue guidance of $220.32-220.32 million, compared to the consensus revenue estimate of $246.44 million.

2 Wall Street analysts have issued 1-year price targets for Amyris' shares. Their forecasts range from $9.00 to $11.00. On average, they expect Amyris' share price to reach $10.00 in the next twelve months. This suggests a possible upside of 109.2% from the stock's current price. View analysts' price targets for Amyris.

News articles about AMRS stock have trended negative recently, according to InfoTrie Sentiment Analysis. The research group scores the sentiment of press coverage by monitoring more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to five, with scores nearest to five being the most favorable. Amyris earned a coverage optimism score of -2.2 on InfoTrie's scale. They also gave news headlines about the biotechnology company a news buzz of 5.0 out of 10, meaning that recent press coverage is somewhat likely to have an effect on the stock's share price in the next several days. View the latest news about Amyris.

Some companies that are related to Amyris include Phillips 66 (PSX), Marathon Petroleum (MPC), Valero Energy (VLO), HollyFrontier (HFC), CVR Energy (CVI), World Fuel Services (INT), Delek US (DK), PBF Energy (PBF), Renewable Energy Group (REGI), Clean Energy Fuels (CLNE), REX American Resources (REX), Green Plains (GPRE), Adams Resources & Energy (AE) and Gevo (GEVO). View all competitors.

Based on aggregate information from My MarketBeat watchlists, some companies that other Amyris investors own include Gevo (GEVO), Keryx Biopharmaceuticals (KERX), Advanced Micro Devices (AMD), Canopy Growth (CGC), Intel (INTC), Inovio Pharmaceuticals (INO), Novavax (NVAX), AT&T (T), Bank of America (BAC) and Corbus Pharmaceuticals (CRBP).

Amyris trades on the NASDAQ under the ticker symbol "AMRS."

Shares of AMRS can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

One share of AMRS stock can currently be purchased for approximately $4.78.

Amyris has a market capitalization of $783.39 million and generates $152.56 million in revenue each year. The biotechnology company earns $-242,770,000.00 in net income (profit) each year or ($2.72) on an earnings per share basis. Amyris employs 414 workers across the globe.

The official website for Amyris is amyris.com.

Amyris' mailing address is 5885 HOLLIS STREET SUITE 100, EMERYVILLE CA, 94608. The biotechnology company can be reached via phone at 510-450-0761 or via email at [email protected]